Bernstein downgrades Summit Therapeutics to Underperform from Market Perform, lowers price target to $8.30

Bernstein downgraded Summit Therapeutics to Underperform, lowering its price target to $8.30 from $11.90, a 30.3% decrease. This implies a 22.2% downside from the Nov 17 close of $10.67. Recent analyst price targets for the company range from $18 to $42.

Original reporting
Published Nov 18, 2026, 12:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bernstein downgrades Summit Therapeutics to Underperform from Market Perform, lowers price target to $8.30 — source image
Decision brief

The 30-second read

$SMMTBearishMed
01

Why it matters

A rating downgrade to Underperform plus a large PT reduction typically increases downside expectations and can influence short-term positioning, especially for momentum or risk-managed funds that track analyst consensus.

02

Market read

Traders may adjust exposure to SMMT based on the downgrade and the implied downside versus the Nov 17 close.

03

What to watch

The article does not state Bernstein’s thesis or any new company-specific data, so traders should verify whether the downgrade reflects new evidence versus valuation or model changes.

Relevance 7/10Novelty 6/10Timing: today, as the downgrade and price-target cut are newly issued

Background

The piece is a sell-side note summary: Bernstein changes Summit Therapeutics’ rating and reduces its target price.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

Bernstein downgraded Summit Therapeutics to Underperform and cut its price target to $8.30 from $11.90, implying downside from the Nov 17 close.

Expected impact

Likely pressure as traders weigh the downgrade and reduced target against existing valuation expectations.

Evidence & confidence

The article provides a clear, time-relevant sell-side action (downgrade plus specific PT cut) with explicit downside math versus the prior close.

Market effects

Could modestly weigh on biotech/small-cap sentiment if investors treat the downgrade as a signal of weaker fundamentals or risk for the group.

Limited, since this is a single-company analyst action rather than a broad macro or sector catalyst.

Low, as the news is US-focused sell-side guidance for one issuer.

Counterpoint

The downgrade may be one analyst’s view; if upcoming clinical or regulatory catalysts are near-term, the stock can ignore PT cuts and trade on event risk instead.

Key entities

  • Summit Therapeutics

    Subject of the downgrade and price-target cut by Bernstein.

  • Bernstein

    Brokerage issuing the Underperform rating and revised $8.30 price target.

Related articles

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$SMMTMed

Summit Therapeutics Plans Global Phase III HARMONi-10 Trial of Ivonescimab

Summit Therapeutics (SMMT) plans a global Phase III trial (HARMONi-10) for ivonescimab vs. durvalumab in treating unresectable Stage III non-small cell lung cancer. The trial, set to begin in Q4 2026, aims to study patients without disease progression after initial treatment, with progression-free survival as the primary endpoint. This is Summit's sixth Phase III ivonescimab study and fourth in this cancer type, according to the company.

$SMMTMed

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung…

Summit Therapeutics Inc. (SMMT) filed an SEC Form 8-K — Other Events. Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Global Registration-Enabling Study to Evaluate Ivonescimab Versus Durvalumab as Consolidation Therapy Following Concurre

$SMMTMedAI 8/10

Summit starts phase 3 trial of ivonescimab in lung cancer

Summit Therapeutics (NASDAQ: SMMT) launched a Phase III trial (HARMONi-10) for ivonescimab in lung cancer, comparing it to durvalumab. The trial aims to evaluate progression-free survival as the primary endpoint, with global site activations expected in Q4 2026. Ivonescimab, a PD-1 x VEGF bispecific antibody, is not approved in the U.S. or Europe but has marketing authorization in China. Over 5,000 patients have been treated in clinical studies globally, and over 100,000 in China.